BirghtInsight Logo 3 24 20.png
BrightInsight Announces Partnership with Sanofi to Bring to Market a Next Generation Digital Companion Application
January 10, 2022 08:30 ET | BrightInsight
SAN JOSE, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- BrightInsight, Inc., provider of the leading global platform for biopharma and medtech regulated digital health solutions, announced today a...
logo.jpg
Sanofi to acquire Amunix immuno-oncology pipeline with next generation Conditionally Activated Biologics
December 20, 2021 23:30 ET | Sanofi - Aventis Groupe
 Sanofi to acquire Amunix immuno-oncology pipeline with next generation Conditionally Activated Biologics Adds promising pipeline of T-cell engagers and cytokine therapies with lead candidate...
logo.jpg
Sanofi va acquérir Amunix pour son portefeuille en immuno-oncologie avec une nouvelle génération d’agents biologiques à activation conditionnelle
December 20, 2021 23:30 ET | Sanofi - Aventis Groupe
Sanofi va acquérir Amunix pour son portefeuille en immuno-oncologie avec une nouvelle génération d’agents biologiques à activation conditionnelle Une opération qui apporte un portefeuille...
BES_Mark.jpg
KADMON ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of KDMN and Encourages Investors to Contact the Firm
September 09, 2021 11:52 ET | Bragar Eagel & Squire
NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or...
BES_Mark.jpg
TRANSLATE BIO ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of TBIO and Encourages Investors to Contact the Firm
August 03, 2021 11:37 ET | Bragar Eagel & Squire
NEW YORK, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors...
TBIO.jpg
Sanofi to Acquire Translate Bio; Advances Deployment of mRNA Technology across Vaccines and Therapeutics Development
August 03, 2021 01:00 ET | Translate Bio, Inc.
-- Accelerates development of current Sanofi licensed programs in vaccines and potential to explore other therapeutic areas -- -- Fast tracks establishment of Sanofi’s recently announced mRNA Center...
TBIO.jpg
Sanofi and Translate Bio Initiate Phase 1 Clinical Trial of mRNA Influenza Vaccine
June 22, 2021 01:00 ET | Translate Bio, Inc.
-- Trial will evaluate potential of next generation of influenza vaccines with combined mRNA technology and flu vaccine development expertise -- -- Positive preclinical safety and immunogenicity data...
Rancho Santa Fe Bio.png
Rancho Santa Fe Bio, Inc. Enters into Worldwide Exclusive License Agreement with Sanofi for Ataciguat
June 17, 2021 05:00 ET | Rancho Santa Fe Bio
SAN DIEGO and PARIS, June 17, 2021 (GLOBE NEWSWIRE) -- Rancho Santa Fe Bio, Inc. (“RSF Bio” or the “Company”), a San Diego, California-based clinical-stage cardiovascular platform company, today...
logo-alt.png
Global Cancer CDK Inhibitor Market 2019-2029 - Pipeline Analysis is estimated to be US$ 16.1 billion by 2030 with a CAGR of 10.4% during the forecast period - by PMI
March 17, 2021 11:35 ET | PMI
Covina CA, March 17, 2021 (GLOBE NEWSWIRE) -- The Global Cancer CDK Inhibitor Market accounted for US$ 6.0 billion in 2019 and is estimated to be US$ 16.1 billion by 2029 and is anticipated to...
logo-alt.png
Global Rare Disease Market is estimated to be US$ 547.5 billion by 2030 with a CAGR of 13.1% during the forecast period - by PMI
February 24, 2021 10:35 ET | PMI
Covina CA, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Global Rare Disease Market accounted for US$ 161.4 billion in 2020 and is estimated to be US$ 547.5 billion by 2030 and is anticipated to register a CAGR...